Drug Profile
Metadoxine extended-release - Arcturus Therapeutics
Alternative Names: MDX; Metadoxine sustained-release; MG-01CI; Pyridoxine pidolate; Pyridoxine pyrrolidone carboxylateLatest Information Update: 05 Oct 2021
Price :
$50
*
At a glance
- Originator Alcobra
- Developer Alcobra; Arcturus Therapeutics
- Class Drug withdrawal therapies; Imino acids; Picolines; Pyrrolidinones; Small molecules; Vitamins
- Mechanism of Action Biogenic monoamine uptake modulators; Neurotransmitter stimulants; Serotonin 2B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Attention-deficit hyperactivity disorder; Fragile X syndrome
Most Recent Events
- 27 Sep 2021 Discontinued - Phase-II for Attention-deficit hyperactivity disorder (In adolescents) in Israel (PO) (Arcturus pipeline, December 2020)
- 27 Sep 2021 Discontinued - Phase-II for Fragile X syndrome (In adolescents, In adults) in USA, Israel (PO) (Arcturus pipeline, December 2020)
- 27 Sep 2021 Discontinued - Phase-III for Attention-deficit hyperactivity disorder (In adults) in USA, Israel (PO) (Arcturus pipeline, December 2020)